CAPE TOWN (Reuters) - South Africa’s drugs regulator SAHPRA said on Wednesday that it had recently reviewed data from Johnson & Johnson’s (J&J) local research study immunising healthcare workers and found no major safety concerns. SAHPRA added that it was awaiting additional data from J&J and the U.S. Food and Drug Administration. South Africa suspended the rollout of the J&J vaccine in the “implementation study” on Tuesday, after U.S. health agencies recommended pausing its use because of rare cases of blood clots in six people inoculated with it.